Clinical Trial Update: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing obinutuzumab with high-dose methylprednisolone in chronic lymphocytic leukemia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• high-dose methylprednisolone (methylprednisolone)

Snippet

Sponsor: University of California, San Diego | Conditions: CLL | Phase 1, Phase 2 | Status: UNKNOWN